ACOR - Acorda Therapeutics GAAP EPS of -$7.55 revenue of $29.68M
2023-08-08 16:41:26 ET
- Acorda Therapeutics press release ( NASDAQ: ACOR ): Q2 GAAP EPS of -$7.55.
- Revenue of $29.68M (-4.4% Y/Y).
- Outlook: For the full year 2023, the Company revised INBRIJA U.S. net revenue guidance to be $34-$38 million, from $38-$42 million. Adjusted OPEX guidance was revised to be $93-$98 million, from $93-$103 million.
- Ending cash balance guidance was revised to be $39-44 million, from $43-$47 million. The Company reaffirms guidance for AMPYRA net revenue to be $65-$70 million. The Company does not expect to be cash flow neutral in 2023.
For further details see:
Acorda Therapeutics GAAP EPS of -$7.55, revenue of $29.68M